NCT01397877已完成2 期
Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy
ARCAGY/ GINECO GROUP45 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 45
- 主要终点
- Clinical Efficacy
研究概览
简要总结
This study is to determine the clinical efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.
Clinical efficacy will be determined by the non-progression rate at 3 or 2 months depending on the group of patients. The primary endpoint is the non-progression rate at 3 months (12 weeks) for the patient group whose disease is painless (low grade tumor = stratum 1) and the non-progression rate at 2 months (8 weeks) for the group of patients with an aggressive disease (high grade tumor = stratum 2).
Disease progression is defined by the RECIST 1.1 criteria
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female ≥ 18 years
- •Histologically confirmed endometrial cancer
- •Not eligible for exclusive curative treatment by surgery and/or radiotherapy
- •Initial metastatic endometrial cancer not treated with chemotherapy or radiotherapy prior to inclusion OR
- •Recurrent endometrial cancer previously treated with adjuvant CT and RT, presenting with a disease-free interval of at least 12 months
- •Presence of one or more measurable lesion(s) outside the irradiated areas
- •Availability at inclusion of samples of tumor tissue (a block or at least 20 unstained slides) for tumor sub-classification and for routine molecular analysis
- •Satisfactory biological functions: PNN ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9.0 g/dL, INR ≤ 2, standard normal values for potassium, calcium and magnesium, serum creatinine ≤ 1.5 x ULN or creatinine clearance > 50 mL/min, ALT and AST within normal range (or ≤ 3.0 x ULN if liver metastases present), Alkaline phosphatase ≤ 2.5 x ULN, serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome), fasting glycemia ≤ 120 mg/dL or ≤ 6.7 mmol/L
- •Life expectancy 3 months
- •Post menopausal woman with at least 12 months of natural (spontaneous) amenorrhea
- •Negative serum pregnancy test ≤ 72 hours prior to initiating treatment for woman of child-bearing potential
- •Consent form signed before any procedure performed
排除标准
- •Previous treatment with PI3K inhibitors and/or mTOR
- •Presence of symptomatic CNS metastases. Patient must have completed any prior treatment for CNS metastases ≥ 28 days and, if on corticosteroid therapy, should be receiving a stable low dose
- •Concomitant presence or history of another malignant tumor in the past 3 years prior to inclusion (except spinocellular or cutaneous basal cell epithelioma or non-melanomatous skin cancer treated successfully)
- •Suffering from mood disorders based on an evaluation by the investigator or a psychiatrist OR with a given score according to the PHQ-9 or GAD-7 mood evaluation scale (cf protocol)
- •Concomitant administration of another approved or investigational anticancer agent
- •Pelvic and/or para-aortic radiotherapy within ≤ 28 days prior to inclusion or persistent side effects from this treatment on implementation of the selection procedures
- •Major surgery during the 28 days prior to starting investigational drug or persistent side effects from surgery
- •Uncontrolled diabetes (HbA1c > 8 %)
- •Presence of an active heart disease, especially: LVEF < 50 % determined by MUGA or ECHO, QTc > 480 msec on ECG recorded during selection (with QTcF formula), angina warranting the administration of anti-angina treatment, ventricular arrhythmia except for benign premature ventricular contractions, supraventricular and nodal arrhythmias warranting a pacemaker or not controlled by a treatment, conduction anomalies warranting a pacemaker, valvular disease with documented involvement of cardiac function, symptomatic pericarditis
- •History of heart disease
- •Currently receiving treatment to prolong QT interval accompanied by a known risk of triggering wave burst arrhythmia. Impossible to stop treatment or to replace it before starting study medication
- •GI dysfunction or disease that could significantly interfere with absorption of BKM120
- •Chronic treatment with corticosteroids or other immunosuppressants
- •Any other severe and/or uncontrolled concomitant disease, which is likely to contraindicate the patient's participation
- •Known treatment non-compliance
- •Currently receiving treatment known to be inhibitors or moderate and strong inducers of isoenzyme CYP3A. Impossible to stop this treatment or to replace it with a different treatment before starting the study product
- •Severe pneumonitis
- •Grade ≥ 3 biological anomalies
- •Known history of HIV infection
- •Pregnant woman or nursing mother
研究组 & 干预措施
stratum 1
Experimental
Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
干预措施: BKM120 (Drug)
结局指标
主要结局
Clinical Efficacy
时间窗: 3 months
To determine the clinical efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.
次要结局
- Efficacy: PFS(6 months)
- Efficacy: ORR(Patient will be followed for the duration of the study, an expected average of 75 days)
- Safety according to CTCAE v4.0 criteria and mood questionnaires : PHQ-9 and GAD-7(Patient will be followed for the duration of the study, an expected average of 75 days)
- Efficacy: overall survival(Patients will be followed for an expected average of 1 year and 75 days)
- Efficacy: duration of response(Patients will be followed for an expected average of 1 year and 75 days)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or ProgressiveHead and Neck NeoplasmsNeoplasm MetastasisRecurrent DiseaseProgressive DiseaseNCT01737450Centre Leon Berard58
已完成
2 期
Safety and Efficacy of BKM120 in Relapsed and Refractory NHLDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaNCT01693614Novartis Pharmaceuticals72
进行中（未招募）
2 期
SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsNCT05631262Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.321
撤回
2 期
BKM120 in Advanced, Metastatic, or Recurrent Endometrial CancersEndometrial CancerNCT01550380University of Utah
已完成
2 期
STAR Cape+BKM120 MBC With Brain MetBrain MetastasesBreast CancerMetastatic Breast CancerNCT02000882US Oncology Research10